{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:24:57Z","timestamp":1787505897082,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04387-5","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:37:54Z","timestamp":1755257874000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing nitazoxanide in type 2 diabetes mellitus: a randomized controlled trial"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-145X","authenticated-orcid":false,"given":"Eman M.","family":"Ghonaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar K.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael F.","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hytham R.","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"4387_CR1","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"U. Galicia-Garcia, A. Benito-Vicente, S. Jebari, L. Larrea-Sebal, H. Siddiqi, K. Uribe, H. Ostolaza, C. Mart\u00edn, Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci. 21, 6275 (2020). https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"Int. J. Mol. Sci."},{"key":"4387_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"X. Lu, Q. Xie, X. Pan, R. Zhang, Z. Zhang, G. Peng, Y. Zhang, S. Shen, N. Tong, Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal. Transduct. Target. Ther. 9, 262 (2024). https:\/\/doi.org\/10.1038\/s41392-024-01951-9.","journal-title":"Signal. Transduct. Target. Ther."},{"key":"4387_CR3","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium. 2021. Available at: https:\/\/diabetesatlas.org\/resources\/previous-editions\/. Accessed 25 Mar 2025."},{"key":"4387_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/14791641241271949","volume":"21","author":"NN Ngcobo","year":"2024","unstructured":"N.N. Ngcobo, N.H. Sibiya, The role of high mobility group box-1 on the development of diabetes complications: a plausible pharmacological target. Diabetes Vasc. Dis. Res. 21, 14791641241271949 (2024). https:\/\/doi.org\/10.1177\/14791641241271949.","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"4387_CR5","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1002\/jcp.27603","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"H. Yaribeygi, F.R. Farrokhi, A.E. Butler, A. Sahebkar, Insulin resistance: review of the underlying molecular mechanisms. J. Cell Physiol. 234, 8152\u20138161 (2019). https:\/\/doi.org\/10.1002\/jcp.27603.","journal-title":"J. Cell Physiol."},{"key":"4387_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"C. Romere, C. Duerrschmid, J. Bournat, P. Constable, M. Jain et al., Asprosin, a fasting-induced glucogenic protein hormone. Cell 165, 566\u2013579 (2016). https:\/\/doi.org\/10.1016\/j.cell.2016.02.063.","journal-title":"Cell"},{"issue":"11","key":"4387_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108614","volume":"37","author":"H Diao","year":"2023","unstructured":"H. Diao, X. Li, Y. Xu, X. Xing, S. Pang, Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus. J. Diabetes Complicat. 37(11), 108614 (2023). https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108614.","journal-title":"J. Diabetes Complicat."},{"issue":"1","key":"4387_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0377-1237(11)80020-1","volume":"67","author":"N Singh","year":"2011","unstructured":"N. Singh, S. Narayan, Nitazoxanide: a broad spectrum antimicrobial. Med. J. Armed Forces India 67(1), 67\u201368 (2011). https:\/\/doi.org\/10.1016\/S0377-1237(11)80020-1.","journal-title":"Med. J. Armed Forces India"},{"key":"4387_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/DDDT.S47173","volume":"7","author":"D Kov\u00e1cs","year":"2013","unstructured":"D. Kov\u00e1cs, Z. Simon, P. H\u00e1ri, A. M\u00e1ln\u00e1si-Csizmadia, C. Hegedus et al., Identification of PPAR\u03b3 ligands with one-dimensional drug profile matching. Drug. Des. Devel Ther. 7, 917\u2013928 (2013). https:\/\/doi.org\/10.2147\/DDDT.S47173.","journal-title":"Drug. Des. Devel Ther."},{"issue":"5","key":"4387_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1139\/cjpp-2017-0533","volume":"96","author":"SM Elaidy","year":"2018","unstructured":"S.M. Elaidy, M.A. Hussain, M.K. El-Kherbetawy, Time-dependent therapeutic roles of nitazoxanide on high-fat diet\/streptozotocin-induced diabetes in rats: effects on hepatic PPAR-\u03b3 receptors. Can. J. Physiol. Pharmacol. 96(5), 485\u2013497 (2018). https:\/\/doi.org\/10.1139\/cjpp-2017-0533.","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"12","key":"4387_CR11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3390\/biom11121817","volume":"11","author":"M Castillo-Salazar","year":"2021","unstructured":"M. Castillo-Salazar, F. S\u00e1nchez-Mu\u00f1oz, R.S. Del Villar, G. Navarrete-V\u00e1zquez, A. Hern\u00e1ndez-Diazcouder et al., Nitazoxanide exerts immunomodulatory effects on peripheral blood mononuclear cells from type 2 diabetes patients. Biomolecules 11(12), 1817 (2021). https:\/\/doi.org\/10.3390\/biom11121817.","journal-title":"Biomolecules"},{"key":"4387_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/bimj.4710380806","volume":"38","author":"M Kieser","year":"1996","unstructured":"M. Kieser, G. Wassmer, On the use of the upper confidence limit for the variance from a pilot sample for sample size determination. Biom. J. 38, 941\u2013949 (1996). https:\/\/doi.org\/10.1002\/bimj.4710380806.","journal-title":"Biom. J."},{"key":"4387_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher et al., Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985). https:\/\/doi.org\/10.1007\/BF00280883.","journal-title":"Diabetologia"},{"key":"4387_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00281-019-00747-2","volume":"41","author":"LL Lehrskov","year":"2019","unstructured":"L.L. Lehrskov, R.H. Christensen, The role of interleukin-6 in glucose homeostasis and lipid metabolism. Semin. Immunopathol. 41, 491\u2013499 (2019). https:\/\/doi.org\/10.1007\/s00281-019-00747-2.","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"4387_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","volume":"27","author":"K Rehman","year":"2017","unstructured":"K. Rehman, M. Sajid, H. Akash, A. Liaqat, S. Kamal et al., Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit. Rev. Eukaryot. Gene Expr. 27(3), 229\u2013236 (2017). https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2017019712.","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"4387_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.24293\/ijcpml.v29i2.1972","volume":"29","author":"M Todingan","year":"2023","unstructured":"M. Todingan, R. Muhiddin, L.B. Kurniawan, IL-6 levels analysis controlled in type 2 diabetes mellitus patients and uncontrolled. Indones. J. Clin. Pathol. Med. Lab. 29, 175\u2013179 (2023). https:\/\/doi.org\/10.24293\/ijcpml.v29i2.1972.","journal-title":"Indones. J. Clin. Pathol. Med. Lab."},{"key":"4387_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s005920050147","volume":"36","author":"S Kado","year":"1999","unstructured":"S. Kado, T. Nagase, N. Nagata, Circulating levels of interleukin-6, its soluble receptor and interleukin-6\/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 36, 67\u201372 (1999). https:\/\/doi.org\/10.1007\/s005920050147.","journal-title":"Acta Diabetol."},{"key":"4387_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-017-0189-z","volume":"17","author":"C Phosat","year":"2017","unstructured":"C. Phosat, P. Panprathip, N. Chumpathat, P. Prangthip, N. Chantratita et al., Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocr. Disord. 17, 1\u20138 (2017). https:\/\/doi.org\/10.1186\/s12902-017-0189-z.","journal-title":"BMC Endocr. Disord."},{"issue":"8","key":"4387_CR19","doi-asserted-by":"publisher","first-page":"e0136564","DOI":"10.1371\/journal.pone.0136564","volume":"10","author":"H Wang","year":"2015","unstructured":"H. Wang, H. Qu, H. Deng, Plasma HMGB-1 levels in subjects with obesity and type 2 diabetes: a cross-sectional study in China. PLoS ONE 10(8), e0136564 (2015). https:\/\/doi.org\/10.1371\/journal.pone.0136564.","journal-title":"PLoS ONE"},{"issue":"1","key":"4387_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9438760","volume":"2016","author":"H Wei","year":"2016","unstructured":"H. Wei, H. Qu, H. Wang, H. Deng, Plasma C1q\/TNF-related protein-3 (CTRP-3) and high-mobility group box-1 (HMGB-1) concentrations in subjects with prediabetes and type 2 diabetes. J. Diabetes Res. 2016(1), 9438760 (2016). https:\/\/doi.org\/10.1155\/2016\/9438760.","journal-title":"J. Diabetes Res."},{"issue":"3","key":"4387_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ21-0381","volume":"69","author":"S Liu","year":"2022","unstructured":"S. Liu, X. Wang, Y. Kai, C. Tian, S. Guo et al., Clinical significance of high mobility group box 1\/toll-like receptor 4 in obese diabetic patients. Endocr. J. 69(3), 235\u2013242 (2022). https:\/\/doi.org\/10.1507\/endocrj.EJ21-0381.","journal-title":"Endocr. J."},{"issue":"1","key":"4387_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3896147","volume":"2016","author":"H Wu","year":"2016","unstructured":"H. Wu, Z. Chen, J. Xie, L.N. Kang, L. Wang et al., High mobility group box-1: a missing link between diabetes and its complications. Mediat. Inflamm. 2016(1), 3896147 (2016). https:\/\/doi.org\/10.1155\/2016\/3896147.","journal-title":"Mediat. Inflamm."},{"issue":"24","key":"4387_CR23","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.3390\/ijms20246258","volume":"20","author":"F Biscetti","year":"2019","unstructured":"F. Biscetti, M.M. Rando, E. Nardella, A.L. Cecchini, G. Pecorini et al., High mobility group box-1 and diabetes mellitus complications: state of the art and future perspectives. Int. J. Mol. Sci. 20(24), 6258 (2019). https:\/\/doi.org\/10.3390\/ijms20246258.","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"4387_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22910","volume":"33","author":"J Huang","year":"2019","unstructured":"J. Huang, T. Zeng, Y. Tian, Y. Wu, J. Yu et al., Clinical significance of high-mobility group box-1 (HMGB1) in subjects with type 2 diabetes mellitus (T2DM) combined with chronic obstructive pulmonary disease (COPD). J. Clin. Lab. Anal. 33(6), e22910 (2019). https:\/\/doi.org\/10.1002\/jcla.22910.","journal-title":"J. Clin. Lab. Anal."},{"key":"4387_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/biom14091123","volume":"14","author":"A Senyigit","year":"2024","unstructured":"A. Senyigit, S. Durmus, R. Gelisgen, H. Uzun, Oxidative stress and asprosin levels in type 2 diabetic patients with good and poor glycemic control. Biomolecules 14, 1123 (2024). https:\/\/doi.org\/10.3390\/biom14091123.","journal-title":"Biomolecules"},{"key":"4387_CR26","doi-asserted-by":"publisher","first-page":"e31334","DOI":"10.1097\/MD.0000000000031334","volume":"101","author":"C Dai","year":"2022","unstructured":"C. Dai, W. Zhu, Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight\/obesity patients with type 2 diabetes mellitus. Medicine 101, e31334 (2022). https:\/\/doi.org\/10.1097\/MD.0000000000031334.","journal-title":"Medicine"},{"issue":"11","key":"4387_CR27","doi-asserted-by":"publisher","first-page":"9149","DOI":"10.1007\/s00210-024-03219-z","volume":"397","author":"SS Talebi","year":"2024","unstructured":"S.S. Talebi, S. Rezaie, M.S. Hajmiri, M. Zamanirafe, A. Ranjbar et al., Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus. Naunyn Schmiedebergs Arch. Pharmacol. 397(11), 9149\u20139165 (2024). https:\/\/doi.org\/10.1007\/s00210-024-03219-z.","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"4387_CR28","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s40618-024-02360-z","volume":"47","author":"Y Zhang","year":"2024","unstructured":"Y. Zhang, P. Yang, X. Zhang, S. Liu, K. Lou, Asprosin: its function as a novel endocrine factor in metabolic-related diseases. J. Endocrinol. Invest. 47, 1839\u20131850 (2024). https:\/\/doi.org\/10.1007\/s40618-024-02360-z.","journal-title":"J. Endocrinol. Invest."},{"issue":"1","key":"4387_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5603\/EP.a2022.0093","volume":"74","author":"G Hu","year":"2023","unstructured":"G. Hu, W. Si, Q. Zhang, F. Lv, Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study. Endokrynol. Pol. 74(1), 55\u201362 (2023). https:\/\/doi.org\/10.5603\/EP.a2022.0093.","journal-title":"Endokrynol. Pol."},{"key":"4387_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2019","unstructured":"L. Zhang, C. Chen, N. Zhou, Y. Fu, X. Cheng, Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin. Chim. Acta 489, 183\u2013188 (2019). https:\/\/doi.org\/10.1016\/j.cca.2017.10.034.","journal-title":"Clin. Chim. Acta"},{"key":"4387_CR31","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.3390\/cimb45080420","volume":"45","author":"A Caturano","year":"2023","unstructured":"A. Caturano, M. D\u2019Angelo, A. Mormone, V. Russo, M.P. Mollica et al., Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications. Curr. Issues Mol. Biol. 45, 6651\u20136666 (2023). https:\/\/doi.org\/10.3390\/cimb45080420.","journal-title":"Curr. Issues Mol. Biol."},{"key":"4387_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s001250051342","volume":"43","author":"DA Slatter","year":"2000","unstructured":"D.A. Slatter, C.H. Bolton, A.J. Bailey, The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 43, 550\u2013557 (2000). https:\/\/doi.org\/10.1007\/s001250051342.","journal-title":"Diabetologia"},{"key":"4387_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/MBC.0b013e3283254549","volume":"20","author":"EA Ei-ghoroury","year":"2009","unstructured":"E.A. Ei-ghoroury, H.M. Raslan, E.A. Badawy, G.S. El-Saaid, M.H. Agybi et al., Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. Blood Coagul. Fibrinolysis 20, 248\u2013251 (2009). https:\/\/doi.org\/10.1097\/MBC.0b013e3283254549.","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"4387_CR34","doi-asserted-by":"publisher","first-page":"e58536","DOI":"10.7759\/cureus.58536","volume":"16","author":"A Sharma","year":"2024","unstructured":"A. Sharma, D. Aruna, A. Beatrice, A study to evaluate the effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on oxidative stress parameters in type 2 diabetes mellitus patients. Cureus 16(4), e58536 (2024). https:\/\/doi.org\/10.7759\/cureus.58536.","journal-title":"Cureus"},{"key":"4387_CR35","doi-asserted-by":"crossref","unstructured":"R.R. Wilcox, in Applying Contemporary Statistical Techniques, (Elsevier, 2003), pp. 557\u2013608","DOI":"10.1016\/B978-012751541-0\/50036-5"},{"key":"4387_CR36","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1002\/fsn3.3530","volume":"11","author":"S Rabizadeh","year":"2023","unstructured":"S. Rabizadeh, F. Heidari, R. Karimi, A. Rajab, S. Rahimi-Dehgolan et al., Vitamin C supplementation lowers advanced glycation end products (AGEs) and malondialdehyde (MDA) in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Food Sci. Nutr. 11, 5967\u20135977 (2023). https:\/\/doi.org\/10.1002\/fsn3.3530.","journal-title":"Food Sci. Nutr."},{"issue":"1","key":"4387_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/820387","volume":"2014","author":"M Arslan","year":"2014","unstructured":"M. Arslan, S.H. Ipekci, L. Kebapcilar, N. Dogan Dede, S. Kurban et al., Effect of aerobic exercise training on MDA and TNF-\u03b1 levels in patients with type 2 diabetes mellitus. Int. Sch. Res. Not. 2014(1), 820387 (2014). https:\/\/doi.org\/10.1155\/2014\/820387.","journal-title":"Int. Sch. Res. Not."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04387-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:09:49Z","timestamp":1761736189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4387"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04387-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Research Ethics Committee of Tanta University and was compliant with the Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided informed consent before being enrolled in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All participants provided informed consent before being enrolled in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}